-
LXEO Dashboard
- Financials
- Filings
-
Holdings
-
Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Lexeo Therapeutics, Inc. Common Stock (LXEO)
Company Profile
Quarter (USD) | Sep 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 160.27 mm | 160.27 mm | 160.27 mm | 160.27 mm | 160.27 mm | 160.27 mm |
Cash burn (monthly) | 12.68 mm | (no burn) | 10.51 mm | 7.51 mm | 176.00 k | 1.39 mm |
Cash used (since last report) | 35.71 mm | n/a | 29.61 mm | 21.14 mm | 495.69 k | 3.90 mm |
Cash remaining | 124.56 mm | n/a | 130.66 mm | 139.13 mm | 159.78 mm | 156.37 mm |
Runway (months of cash) | 9.8 | n/a | 12.4 | 18.5 | 907.8 | 112.8 |
13F holders | Current |
---|---|
Total holders | 72 |
Opened positions | 19 |
Closed positions | 6 |
Increased positions | 36 |
Reduced positions | 9 |
13F shares | Current |
---|---|
Total value | 268.34 bn |
Total shares | 36.04 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
JHG Janus Henderson | 3.76 mm | $34.00 bn |
Longitude Capital Partners IV | 2.77 mm | $22.90 mm |
Citadel Advisors | 2.72 mm | $24.62 bn |
Adage Capital Partners GP, L.L.C. | 2.60 mm | $23.48 bn |
Adage Capital Management | 2.60 mm | $21.51 mm |
D1 Capital Partners | 2.51 mm | $22.66 bn |
Omega Fund Management | 2.36 mm | $21.30 bn |
Eventide Asset Managment | 1.86 mm | $16.78 bn |
BlackRock | 1.63 mm | $14.74 bn |
Frazier Life Sciences Management | 1.25 mm | $11.31 bn |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
10 Dec 24 | Richard Nolan Townsend | Common Stock | Sell | Dispose S | No | Yes | 8.1965 | 2,500 | 20.49 k | 120,695 |
10 Dec 24 | Richard Nolan Townsend | Common Stock | Option exercise | Acquire M | No | Yes | 2.33 | 2,500 | 5.83 k | 123,195 |
10 Dec 24 | Richard Nolan Townsend | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 2.33 | 2,500 | 5.83 k | 118,655 |
25 Nov 24 | Cholmondeley Paula H | Common Stock | Buy | Acquire P | No | No | 6.9901 | 15,000 | 104.85 k | 30,627 |
11 Nov 24 | Tolga Tanguler | Stock Option Common Stock | Grant | Acquire A | No | No | 7.95 | 36,000 | 286.20 k | 36,000 |
11 Nov 24 | Richard Nolan Townsend | Common Stock | Sell | Dispose S | No | Yes | 7.8227 | 2,500 | 19.56 k | 120,695 |
11 Nov 24 | Richard Nolan Townsend | Common Stock | Option exercise | Acquire M | No | Yes | 2.33 | 2,500 | 5.83 k | 123,195 |
11 Nov 24 | Richard Nolan Townsend | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 2.33 | 2,500 | 5.83 k | 121,155 |